Diagnostic value of PSA, TAP and MACC1 expression in blood of patients with prostate cancer

doi:10.3969/j.issn.1674-8115.2022.04.012

Abstract

Abstract: Objective

·To investigate the expression and diagnostic value of prostate specific antigen (PSA), tumor abnormal protein (TAP) and colon cancer metastasis related gene 1 (MACC1) in the blood of patients with prostate cancer.

Methods

·One hundred and seven patients with prostate cancer (case group) admitted to Dahua Hospital, Xuhui District, Shanghai, from January 2019 to December 2020 were retrospectively analyzed, and 60 healthy people (control group) who underwent physical examination in the hospital in the same period were selected. The levels of blood PSA, TAP and MACC1 in the two groups, as well as their correlation with Gleason score and T stage, were analyzed. Receiver operating characteristic (ROC) curve was used to evaluate the value of various indexes in the diagnosis of prostate cancer.

Results

·The levels of blood PSA, TAP and MACC1 in the case group were significantly higher than those in the control group (P<0.05). With the increase of Gleason grade, the levels of blood PSA, TAP and MACC1 increased gradually. With the progress of T stage, the levels of blood PSA, TAP and MACC1 increased gradually. The levels of PSA and MACC1 in the patients with lymph node metastasis were significantly higher than those without lymph node metastasis, but the levels of TAP in the patients with lymph node metastasis were significantly lower than those without lymph node metastasis (P<0.05). The analysis results of ROC curve showed that the AUC of PSA in the diagnosis of prostate cancer was 0.764, the sensitivity was 86.12%, the specificity was 88.63%, and the cut-off value was 6.01 μg/L. The AUC of TAP in the diagnosis of prostate cancer was 0.796, the sensitivity was 88.18%, the specificity was 89.58%, and the cut-off value was 135.62 μm². The AUC of MACC1 in the diagnosis of prostate cancer was 0.873, the sensitivity was 78.46%, the specificity was 80.10%, and the cut-off value was 37.80 pg/mL. The AUC (0.941), sensitivity (93.15%) and specificity (94.08%) of combined detection were higher than those of any single detection (P<0.05). Spearman correlation analysis showed that the blood PSA, TAP and MACC1 levels were positively correlated with Gleason score (r=0.648, 0.513, 0.501; P=0.000), and with T stage (r=0.616, 0.537, 0.542; P=0.000).

Conclusion

·Blood PSA, TAP and MACC1 are closely related to Gleason score and T stage of prostate cancer, which has some value in the diagnosis of prostate cancer, and the combined detection of three items has higher diagnostic value.

Key words: prostate specific antigen (PSA), tumor abnormal protein (TAP), colon cancer metastasis related gene 1 (MACC1), prostate cancer, Gleason score, T stage

CLC Number:

R737.25

WANG Hui, ZHAO Ying, WEN Lirong, CAO Jun, YANG Jiping, YUAN Yongming. Diagnostic value of PSA, TAP and MACC1 expression in blood of patients with prostate cancer[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(4): 496-501.

Figures/Tables 3

TrendMD

References 17

1	刘畅, 王庆伟, 罗振宇, 等.SKP2、kindlin-2在前列腺癌组织中的表达及其与患者临床特征的关系[J].癌症进展, 2019, 17(6):727-730.
	LIU C, WANG Q W, LUO Z Y, et al.Expression of SKP2 and kindlin-2 in prostate cancer and the relationship with clinical characteristics[J].Oncol Prog, 2019, 17(6):727-730.
2	陈勇杰, 许春. miR-18a在前列腺癌患者血清中的表达及其临床意义[J]. 国际泌尿系统杂志, 2020(1): 34-37.
	CHEN Y J, XU C.Expression of miR-18a in serum of patients with prostate cancer and its clinical significance[J].Int J Urol Nephrol,2020(1): 34-37.
3	Chung H Y, Kim J H, Han I H, et al. Polarization of M2 macrophages by interaction between prostate cancer cells treated with trichomonas vaginalis and adipocytes[J]. Korean J Parasitol, 2020, 58(3): 217-227.
4	王长春, 尹水平, 李家山, 等. 前列腺特异性抗原联合肿瘤异常蛋白对前列腺癌的诊断价值[J]. 临床泌尿外科杂志, 2019, 34(10): 791-795.
	WANG C C,YIN S P, LI J S, et al. Clinical value of PSA combined with TAP in the diagnosis of prostate cancer[J].J Clin Urol, 2019, 34(10): 791-795.
5	郑建坤, 周园, 宏小翠, 等. 结肠癌转移相关基因1和胸苷激酶1在前列腺癌组织的表达及其临床意义[J]. 中华实验外科杂志, 2018, 35(12): 2196-2198.
	ZHEN J K, ZHOU Y, HONG X C, et al.Study of the expression of metastasis-associated in colon cancer 1, thymidine kinase 1 and the clinical significance of prostate carcinoma[J].Chin J Exper Surg,2018, 35(12): 2196-2198.
6	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国前列腺癌放射治疗指南(2020年版)[J]. 中华肿瘤防治杂志, 2021, 28(5): 323-337.
	Radiation Tumor Therapy Branch of Chinese Medical Association, Chinese Society of Radiation Oncology, Tumor Radiation Therapy Professional Committee of Chinese Anti-Cancer Association.Guidelines for radiotherapy of prostate cancer in China (2020 Edition)[J].Chin J Cancer Prev Treat, 2021, 28(5): 323-337.
7	中华医学会病理学分会泌尿与男性生殖系统疾病病理学组. 前列腺癌规范化标本取材及病理诊断共识(2021版)[J]. 中华病理学杂志, 2021, 50(9): 994-1001.
	Pathology Group of Urological and Male Reproductive System Diseases, Pathology Branch of Chinese Medical Association. Consensus on standardized specimen selection and pathological diagnosis of prostate cancer (2021 edition)[J].Chin J Pathol, 2021, 50(9): 994-1001.
8	吴怀申, 何雍毅. 恶性肿瘤的TNM分类法[J]. 癌症, 1999,18(1): 104-105.
	WU H S, HE Y Y.TNM classification of malignant tumors[J].Cancer,1999, 18(1): 104-105.
9	International Agency for Research on Cancer. Latest global cancer data: cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020[EB/OL].(2020-12-15)[2021-12-15].https://www.iarc.who.int/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020.
10	姚韧寰, 王红梅, 胡敏, 等. 前列腺癌ADC值与血清IL-6、VEGF、PSA的相关性分析[J]. 现代肿瘤医学, 2019, 27(10): 1757-1760.
	YAO R H, WANG H M, HU M, et al. Analysis of correlation between ADC value and serum IL-6,VEGF,PSA in prostate cancer[J].Modern Oncol, 2019, 27(10): 1757-1760.
11	李绍成, 骆本军, 罗建蓉. 前列腺癌患者血清PSA表达情况及PCNA表达的相关性研究[J]. 中国性科学, 2018, 27(8): 14-18.
	LI S C, LUO B J, LUO J R. The expression of serum PSA in patients with prostate cancer and its correlation with the expression of PCNA[J]. Chin J Hum Sex, 2018, 27(8): 14-18.
12	蒋丽琳, 肖南平, 蒋欢. 胃癌组织中BRCA1蛋白表达、血清TAP水平变化与铂类化疗效果的关系分析[J]. 癌症进展, 2019, 17(6): 715-718.
	JIANG L L, XIAO N P, JIANG H. Relationship between expression of BRCA1 protein,serum TAP and the efficacy of platinum-based chemotherapy in patients with gastric cancer[J].Oncol Prog, 2019, 17(6): 715-718.
13	Welch H G, Albertsen P C. Reconsidering prostate cancer mortality: the future of PSA screening[J]. N Engl J Med,2020,382(16):1557-1563.
14	杨双祥, 周永安, 黄娅芬, 等. 腹腔镜宫颈癌根治术后TAP、CEA水平变化及其临床意义[J]. 局解手术学杂志, 2018, 27(6): 447-450.
	YANG S S, ZHOU Y A, HUANG Y F, et al.Changes in TAP and CEA after laparoscopic radical resection of cervical cancer and their clinical significance[J].J Reg Anat Oper Surg, 2018, 27(6): 447-450.
15	刘伟刚, 刘家炜, 王旭东. 前列腺癌患者血清MACC1的表达水平及其与临床病理参数和预后的关系[J]. 解放军预防医学杂志, 2019, 37(8): 65-66.
	LIU W G, LIU J W, WANG X D.Serum MACC1 expression level and its relationship with clinicopathological parameters and prognosis in patients with prostate cancer[J].J Prev Med Chin Peopl Liber Army,2019, 37(8): 65-66.
16	韩刚, 龚航军, 曹羽, 等. 结肠癌患者血清MACC1、CEA表达水平与腹腔镜术后复发转移的相关性[J]. 中国现代普通外科进展, 2019, 22(10): 757-760.
	HAN G, GONG H J, CAO Y, et al. Correlation of serum MACC1 and CEA levels with recurrence and metastasis after laparoscopic surgery in patients with colon cancer[J].Chin J Curr Adv Gen Surg, 2019, 22(10): 757-760.
17	陈钇地, 龙莉玲, 彭鹏, 等. DCE-MRI定量参数与前列腺癌Gleason评分及血清PSA相关性分析的价值[J]. 临床放射学杂志, 2018, 37(10): 1693-1697.
	CHEN Y D, LONG L L, PENG P, et al. The value of correlation analysis between quantitative parameters of DCE-MRI with gleason score of prostate cancer and serum PSA[J].J Clin Radiol, 2018, 37(10): 1693-1697.

Group	PSA/ （μg‧L^-1）	TAP/μm²	MACC1/ （ng‧mL^-1）
Case group （n=107）	14.35±5.13	174.58±19.63	52.41±12.89
Control group （n=60）	4.16±1.34	74.29±8.04	29.84±6.33
t value	15.082	37.796	12.718
P value	0.000	0.000	0.000

Group	PSA/ （μg‧L^-1）	TAP/μm²	MACC1/ （ng‧mL^-1）
Case group （n=107）	14.35±5.13	174.58±19.63	52.41±12.89
Control group （n=60）	4.16±1.34	74.29±8.04	29.84±6.33
t value	15.082	37.796	12.718
P value	0.000	0.000	0.000

Clinic pathologic feature	n	PSA/ （μg‧L^-1）	TAP/μm²	MACC1/ （ng‧mL^-1）
Age
<65 years	54	14.15±5.08	175.54±20.15	52.18±12.91
≥65years	53	14.55±5.26	173.60±20.25	52.64±13.07
t/F value		0.400	0.467	0.183
P value		0.689	0.620	0.855
Gleason score
2‒4 score	7	9.25±4.12	148.34±18.58	39.95±10.23
5‒7 score	48	14.08±5.03	172.18±19.22	50.89±12.83
8‒10 score	52	19.31±5.19	201.41±19.34	65.66±13.04
t/F value		20.599	42.023	23.543
P value		0.000	0.000	0.000
T satge
T1	29	9.14±3.26	146.12±19.12	40.16±10.25
T2	47	14.19±4.89	168.58±19.58	51.97±12.78
T3‒T4	31	17.79±4.93	199.37±20.12	60.58±12.83
t/F value		27.629	56.084	21.247
P value		0.000	0.000	0.000
Lymphatic metastasis
Yes	62	16.58±6.12	121.48±20.59	73.53±6.58
No	45	11.28±5.89	147.07±19.87	37.08±5.03
t/F value		4.492	6.439	31.127
P value		0.000	0.000	0.000

Clinic pathologic feature	n	PSA/ （μg‧L^-1）	TAP/μm²	MACC1/ （ng‧mL^-1）
Age
<65 years	54	14.15±5.08	175.54±20.15	52.18±12.91
≥65years	53	14.55±5.26	173.60±20.25	52.64±13.07
t/F value		0.400	0.467	0.183
P value		0.689	0.620	0.855
Gleason score
2‒4 score	7	9.25±4.12	148.34±18.58	39.95±10.23
5‒7 score	48	14.08±5.03	172.18±19.22	50.89±12.83
8‒10 score	52	19.31±5.19	201.41±19.34	65.66±13.04
t/F value		20.599	42.023	23.543
P value		0.000	0.000	0.000
T satge
T1	29	9.14±3.26	146.12±19.12	40.16±10.25
T2	47	14.19±4.89	168.58±19.58	51.97±12.78
T3‒T4	31	17.79±4.93	199.37±20.12	60.58±12.83
t/F value		27.629	56.084	21.247
P value		0.000	0.000	0.000
Lymphatic metastasis
Yes	62	16.58±6.12	121.48±20.59	73.53±6.58
No	45	11.28±5.89	147.07±19.87	37.08±5.03
t/F value		4.492	6.439	31.127
P value		0.000	0.000	0.000

[1]	SONG Xu-jia, ZHANG Shi-jun, Lü Wen-xin, HUANG Lin, ZHANG Yan, WU Ming-gui, XIE Shao-wei. Synergistic chemo-photothermal therapy of castration-resistant prostate cancersingle-walled carbon nanotube [J]. , 2020, 40(4): 450-.
[2]	HONG Xi1, LIU Li-jie1, HUANG Xian-yu2, LUO Jing2, YU Jian-jun1. Effects of BRD4 inhibitor on histone crotonylation, proliferation and migration of prostate cancer cells [J]. , 2019, 39(7): 721-.
[3]	XIE Shao-wei,DONG Bai-jun,XIA Jian-guo,WANG Yan-qing,LI Hong-li,ZHANG Shi-jun,YANG Wen-qi,LI Feng-hua. Value of prostate anterior horn biopsy in the diagnosis of prostate cancer [J]. , 2019, 39(5): 518-.
[4]	FANG Xiao1, 2, GUO Jian-gong1, HUANG Jin-ming1, FAN Lian-cheng2. Prediction of prognostic nutritional index for the primary resistance to abiraterone and the prognosis in metastatic castration-resistant prostate cancer patients [J]. , 2019, 39(3): 316-.
[5]	CHEN Ming, FU Xiao-hong, WU Shu, WAN Yong-lin. Risk estimation of prostate cancer in patients with serum prostate-specific antigen level of 4–10 ng/mL [J]. , 2019, 39(2): 217-.
[6]	LIU Li-jie1, HONG Xi1, HUANG Xian-yu3, LUO Jing3, YU Jian-jun1, 2. Global levels of lysine crotonylation in prostate cancer and its correlation with clinical stages and pathologic grades [J]. , 2018, 38(7): 788-.
[7]	PAN Yu-long1, QI Jun2, ZHOU Liang1, ZHANG Tong-tong1, LI Qiang1. Ribosomal protein 16 overexpresses in prostate cancer and promotes tumor progression [J]. , 2018, 38(4): 394-.
[8]	PAN Jia-hua, CHI Chen-fei, DONG Bai-jun, ZHU Yin-jie, SHAO Xiao-guang, WANG Yan-qing, XU Fan, SHA Jian-jun, HUANG Yi-ran, XUE Wei . Safety of neoadjuvant chemo-hormonal therapy by the combination of docetaxel and maximal androgen blockage for locally advanced prostate cancer [J]. , 2017, 37(6): 797-.
[9]	FAN Lian-cheng, DONG Bai-jun, CHI Chen-fei, PAN Jia-hua, WANG Yan-qing, SHAO Xiao-guang, XU Fan, SHANGGUAN Xun, ZHOU Li-xin#, XUE Wei# . Efficacy and prognostic factors of abiraterone combined with prednisone treating metastatic castration- resistant prostate cancer patients#br# [J]. , 2017, 37(11): 1483-.
[10]	FU Shi, ZHOU Juan, WANG Zhong . Research progresses on the role of adiponectin and its receptors in prostate cancer#br# [J]. , 2017, 37(10): 1434-.
[11]	FAN Lian-cheng, DONG Bai-jun, CHI Chen-fei, PAN Jia-hua, SHA Jian-jun, HUANG Yi-ran, ZHOU Li-xin, XUE Wei. Efficacy and safety of abiraterone combined with prednisone for treating chemotherapy-naive metastatic castration-resistant prostate cancer [J]. , 2016, 36(9): 1306-.
[12]	CHEN Xiao-xi, WU Lian-ming, ZHANG Xiao-fei, et al. Correlation between IVIM diffusion-weighted MR imaging and Gleason score of prostate cancer [J]. , 2014, 34(6): 868-.
[13]	YANG Yan, CHEN Li. Factors and interventions for mental disorders in patients with prostate cancer after androgen deprivation therapy [J]. , 2011, 31(6): 730-.
[14]	DING Yi-xing, QI Juan. Research progress and clinical implication prospect of TMPRSS2-ETS fusion gene in prostate cancer [J]. , 2011, 31(6): 852-.
[15]	WU Qi-jun, XU Jian-feng, SHI Rong. Research progress of susceptible genes and genetic epidemiology of prostate cancer [J]. , 2011, 31(5): 672-.